Skip to Main Content
Table 3—

Changes in blood pressure and albuminuria over dietary phases in placebo and losartan groups

Placebo
Losartan
Regular sodiumLow sodiumRegular sodiumLow sodium
MAP (mmHg) −1.3 ± 2.2 −5.9 ± 2.2 −9.9 ± 2.0* −12.1 ± 1.7 
AER (%) −4.4 (−19.9 and 7.3) −30.1 (−35.9 and −7.1) 14.1 (−44.7 and 55.7) −53.3 (−60.0 and −32.9) 
Placebo
Losartan
Regular sodiumLow sodiumRegular sodiumLow sodium
MAP (mmHg) −1.3 ± 2.2 −5.9 ± 2.2 −9.9 ± 2.0* −12.1 ± 1.7 
AER (%) −4.4 (−19.9 and 7.3) −30.1 (−35.9 and −7.1) 14.1 (−44.7 and 55.7) −53.3 (−60.0 and −32.9) 

Data are means ± SE or median (interquartile range).

*

P = 0.01 vs. placebo regular-sodium phase;

P = 0.04 vs. placebo low-sodium phase;

P = 0.02 vs. losartan regular-sodium phase.

Close Modal

or Create an Account

Close Modal
Close Modal